ALNY — Alnylam Pharmaceuticals, Inc.
$165.04
+$8.39 (+5.36%)
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
Market Cap
$22.11B
Forward P/E
15.2x
52-Week Range
N/A
ALNY Price History
Revenue vs. Net Income
$3.7B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$465M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
16.5%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.2x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
1.6%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+5.5%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
